Foundation Medicine and Syndax Pharmaceuticals have initiated a partnership to develop a tool to identify acute myeloid leukemia (AML) patients with NPM1 mutations.
NPM1 mutations are common in AML, affecting around 30% of newly diagnosed patients. However, there are currently no approved targeted treatments for these patients, with an overall survival rate of approximately 50% after five years.
Menin inhibitors, such as Syndax’s revumenib, are promising new treatment options for NPM1-mutated AML. To enhance the identification of suitable patients, Foundation Medicine aims to create a next-generation sequencing companion diagnostic based on its FoundationOne® Heme platform.
This assay, if approved, could lead to more personalized and effective treatment options for AML patients. It could also mark the platform’s first use as a companion diagnostic, solidifying Foundation Medicine’s position as the industry leader in companion diagnostic approvals.
The collaboration underscores the importance of advancing comprehensive genomic profiling and developing new therapeutic targets in the fight against blood cancers. By providing physicians with access to high-quality tests and potential therapies, the partnership aims to improve patient outcomes and optimize treatment decisions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
